12.71
-0.89(-6.54%)
Currency In USD
| Previous Close | 13.6 |
| Open | 13.56 |
| Day High | 13.65 |
| Day Low | 12.7 |
| 52-Week High | 13.85 |
| 52-Week Low | 5.79 |
| Volume | 2.21M |
| Average Volume | 2.46M |
| Market Cap | 2.21B |
| PE | -10.09 |
| EPS | -1.26 |
| Moving Average 50 Days | 11.69 |
| Moving Average 200 Days | 8.91 |
| Change | -0.89 |
If you invested $1000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, it would be worth $725.87 as of September 09, 2025 at a share price of $12.71. Whereas If you bought $1000 worth of Ocular Therapeutix, Inc. (OCUL) shares 5 years ago, it would be worth $1,538.74 as of September 09, 2025 at a share price of $12.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocular Therapeutix™ to Host Investor Day on September 30, 2025
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease experts Dr. Arshad M. Khanani MD, MA, FASRS; Professo
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
GlobeNewswire Inc.
Aug 27, 2025 11:00 AM GMT
BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor a
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
GlobeNewswire Inc.
Aug 12, 2025 11:00 AM GMT
Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIR